IL6 and breast carcinoma: Therefore, determining the detailed molecular mechanisms that regulate IL-6-dependent recruitment and amplification of MDSCs in breast cancer may help screen for potential therapeutic targets to eradicate MDSCs and reverse MDSCs-mediated immune tolerance in breast cancer patients.